Der Orthopäde

, Volume 36, Issue 2, pp 110–117 | Cite as

Bisphosphonate in der Osteoporosetherapie

Standards und Perspektiven
  • S. Reinsdorf
  • B. Habermann
  • K. Hochmuth
  • A.A. Kurth
Leitthema
  • 100 Downloads

Zusammenfassung

Die Substanzgruppe der Bisphosphonate setzt sich aus potenten Inhibitoren der Knochenresorption zusammen, welche eine präverierte Therapie für die Prävention und für die Therapie der Osteoporose darstellt. Zahllose klinische Studien haben eine konsistente Reduktion des Risikos für vertebrale Frakturen unter dem Einsatz der Bisphosphonate erbracht. Des Weiteren konnte klar eine Reduktion des Hüftfrakturrisikos und des Risikos für andere nicht-vertebrale Frakturen erbracht werden.

Die Bisphosphonate werden nach ihrer Potenz und der chemischen Struktur in 3 Generationen eingeteilt. Insgesamt als Substanzgruppe wird dies sehr gut vertragen und Toxizitäten bei richtiger Anwendung sind gering. Alternative Dosierungen, z. B. monatlich, 3-monatlich oder jährlich als orale oder i.v.-Gabe werden wahrscheinlich die Compliance der Patienten verbessern. Des Weiteren konnte in den klinischen Studien die Sicherheit und die Effektivität der Bisphosphonate über einen Zeitraum von 3-7 Jahren nachgewiesen werden.

Schlüsselwörter

Bisphosphonate Osteoporose Frakturen 

Bisphosphonates in osteoporosis therapy

Standards and perspectives

Abstract

Bisphosphonates are potent inhibitors of bone resorption and approved agents for both the prevention and treatment of osteoporosis. Many clinical studies have shown a consistent reduction in the risk of vertebral fractures with the use of these drugs, while others have shown a clear reduction in the risk of hip and other non-vertebral fractures.

The bisphosphonates are divided into three generations based on their potency and chemical structure. In general, as a substance group they are well tolerated and, when applied correctly, the toxicity is low. Alternative dosages, e.g. monthly, three times a month or yearly as an oral drug or i.v. would probably improve patient compliance. Clinical studies have also shown the safety and effectiveness of bisphosphonates over a period of 3–7 years.

Keywords

Bisphosphonates Osteoporosis Fractures 

Notes

Interessenkonflikt

Der korrespondierende Autor hat einen Interessenkonflikt, da er für die Firmen der angegebenen Produkte im Rahmen von klinischen Studien und in wissenschaftlichen Beiräten tätig war oder ist sowie Vorträge über die Produkte gehalten hat.

Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Literatur

  1. 1.
    Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355: 2048–2050CrossRefGoogle Scholar
  2. 2.
    Black D, Schwartz A, Ensrud K et al. (2004) A 5 year randomized trial of the long-term efficary and safety of alendronate: The FIT Long-term Extension (FLEX). J Bone Miner Metab 19(Suppl 1): 45Google Scholar
  3. 3.
    Black DM, Thompson DE, Bauer DC et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: theFracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 4118–4124CrossRefPubMedGoogle Scholar
  4. 4.
    Bone HG, Hosking D, Devogelaer JP et al. (2004) Ten years‘ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199CrossRefPubMedGoogle Scholar
  5. 5.
    Boonen S, Orwoll ES, Wenderoth D et al. (2006) Risedronate is effective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status. ASMBR 2006: 346Google Scholar
  6. 6.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion and infusion given once every 3 months, and calcium alone. J Bone Miner Res 16: 104–112CrossRefPubMedGoogle Scholar
  7. 7.
    Chestnut III CH, Skag A, Christiansen C et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249CrossRefPubMedGoogle Scholar
  8. 8.
    Chesnut III CH, Ettinger MP, Miller PD et al. (2005) Ibandronate producessignificant, similar antifractureefficacy in North American and European women: new clinicalfindings from bone. Curr Med Res Opin 2005: 21391–2401Google Scholar
  9. 9.
    Cohen S, Levy RM, Keller M et al. (1999) Risedronates therapy prevents corticosteroid-induced osteoporosis bone loss. Arthritis Rheum 42: 2309–2318CrossRefPubMedGoogle Scholar
  10. 10.
    Cranney A, Guyatt G, Krolickin et al. (2001) A metaanalysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Research Advisory Group. Osteoporos Int 12: 140–151CrossRefPubMedGoogle Scholar
  11. 11.
    Delmas PD, Adami S, Strugala C et al. (2006) Intravenous Ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Art Rheum 54: 1838–1846CrossRefGoogle Scholar
  12. 12.
    Eastell R, Barton I, Hannon R et al. (2001) Antifracture efficacy of risedronate prediction by change in bone resorption markers. J Bone Miner Res 16: 163Google Scholar
  13. 13.
    Felsenberg D, Hoffmeister B, Amling M et al. (2006) Kiefernekrosen nach hoch dosierterBisphosphonattherapie. Dtsch Arztebl A 103: 3078–3080Google Scholar
  14. 14.
    Felsenberg D, Miller PD, Armbrecht G et al. (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37: 651–654CrossRefPubMedGoogle Scholar
  15. 15.
    Fleisch H (1998) Bisphosphonates: mechanisms of action. Endo Rev 19: 80–100CrossRefGoogle Scholar
  16. 16.
    Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352CrossRefPubMedGoogle Scholar
  17. 17.
    Heijckmann AC, Juttman JR, Wolffenbuttel BH (2002) Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 60: 315–319PubMedGoogle Scholar
  18. 18.
    Mashiba T, Turner CH, Hirano T et al. (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524–531CrossRefPubMedGoogle Scholar
  19. 19.
    McCloskey E, Selby P, deTakats D et al. (2001) Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 28: 310–315CrossRefPubMedGoogle Scholar
  20. 20.
    McClung M, Geusens P, Miller P et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333–340CrossRefPubMedGoogle Scholar
  21. 21.
    Mellstrom DD, Sorensen OH, Goemaere S et al. (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 462–468CrossRefPubMedGoogle Scholar
  22. 22.
    Miller PD, Watts NB, Licata AA et al. (1997) Cyclic etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 103: 468–476CrossRefPubMedGoogle Scholar
  23. 23.
    Miller PD, McClung MR, Macovei L et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315–1322CrossRefPubMedGoogle Scholar
  24. 24.
    Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604–610CrossRefPubMedGoogle Scholar
  25. 25.
    Pols HA, Felsenberg D, Hanley DA et al. (1999) Multinational, placebo-controlled, randomized trial of the effects ofalendronate on bone density and fracture risk in postmenopausal women with lowbone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9: 461–468CrossRefPubMedGoogle Scholar
  26. 26.
    Recker R, Ensrud K, Diem S et al. (2004) Normal Bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Metab 19(Suppl 1): 45Google Scholar
  27. 27.
    Reginster J, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with estabilished postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83–91CrossRefPubMedGoogle Scholar
  28. 28.
    Reginster JY, Lecart MP, Deroisy R, et al. (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet 2: 1469–1471CrossRefPubMedGoogle Scholar
  29. 29.
    ReginsterJY, Adami S, Lakatos P et al. (2006) Efficacy and tolerability of once-monthly oralibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 65: 654–661CrossRefPubMedGoogle Scholar
  30. 30.
    Reid DM, Hughes RA, Laan RF et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-indurced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15: 1006–1123CrossRefPubMedGoogle Scholar
  31. 31.
    Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in cortcosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14: 801–807CrossRefPubMedGoogle Scholar
  32. 32.
    Rogers MJ, Russell RGG (1999) Bisphosphonates: from the labortory to the clinic and back again. Bone 25: 97–106CrossRefPubMedGoogle Scholar
  33. 33.
    Roux C, Seeman E, Eastell R et al. (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20: 433–439CrossRefPubMedGoogle Scholar
  34. 34.
    Saag KG, Emkey R, Schnitzer TJ et al. (1998) Alendronate fort he prevention and treatment of glucocorticoid-induced osteoporosis. N Eng J Med 339: 292–299CrossRefGoogle Scholar
  35. 35.
    Silverman SL, Watts NB, Delmas PD et al. (2006) Effectiveness of bisphosphonates on nonvertebral and hipfractures in the first year of therapy: The risedronateand alendronate (REAL) cohort study. Osteoporos Int DOI 10.1007/s00198–006–0274Google Scholar
  36. 36.
    Storm T, Kollerup G, Thamsborg G et al. (1996) Five years of clinical experience with intermittent cyclic etidronate for postmenopausal osteoporosis. J Rheumatol 23: 1560–1564PubMedGoogle Scholar
  37. 37.
    Thiebaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103: 298–307CrossRefPubMedGoogle Scholar
  38. 38.
    Van Beek ER, Lowik CW. Papapoulos SE (2002) Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30: 64–70CrossRefPubMedGoogle Scholar
  39. 39.
    van Staa TP, Abenhaim L, Cooper C (1998) Use of cyclic etidronate and prevention of nonvertebral fractures. Br J Rheumatol 37: 87–94CrossRefPubMedGoogle Scholar
  40. 40.
    Vasikaran SD (2001) Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38: 608–623CrossRefPubMedGoogle Scholar
  41. 41.
    Vis M, Bultink L, Dijkmans B, Lems W (2004) The effect of oral alendronate versus intravenous pamindronate on bone mineral density in patients with osteoporosis. J Bone Miner Metab 19(Suppl 1): 311Google Scholar
  42. 42.
    Watts N, Adami S, Chesnut CH 3rd et al. (2001) Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 16: 407Google Scholar
  43. 43.
    Watts NB (2001) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27: 197–214CrossRefPubMedGoogle Scholar
  44. 44.
    Whyte MP, Wenkert D, Clements KL et al. (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457–463CrossRefPubMedGoogle Scholar
  45. 45.
    Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104: 219–226CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  • S. Reinsdorf
    • 1
  • B. Habermann
    • 2
  • K. Hochmuth
    • 2
  • A.A. Kurth
    • 2
  1. 1.Ortopädische Praxis am FürstenhofFrankfurtDeutschland
  2. 2.Orthopädische Universitätsklinik Frankfurt, Stiftung FriedrichsheimFrankfurtDeutschland

Personalised recommendations